Alaunos Therapeutics Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Cash & Equivalents	1.39	1.09	6.06	39.06	76.05
Cash & Short-Term Investments	1.39	1.09	6.06	39.06	76.05
Cash Growth	26.95%	-82.00%	-84.48%	-48.64%	-33.91%
Accounts Receivable	0	0.01	0	0	-
Other Current Assets	0.6	1.66	2.2	14.74	2.78
Total Current Assets	1.99	2.76	8.26	53.8	78.83
Net Property, Plant & Equipment	0.09	-	0	10.6	15.36
Other Long-Term Assets	0.89	-	-	0.54	0.67
Total Assets	2.97	2.76	8.26	64.94	94.87
Accounts Payable	0.61	0.52	0.62	1.39	1.37
Accrued Expenses	0.2	0.18	1.34	5.45	6.08
Current Portion of Long-Term Debt	-	-	-	16.77	7.87
Current Portion of Leases	-	-	-	0.56	0.73
Total Current Liabilities	0.81	0.69	1.96	24.17	16.04
Long-Term Debt	-	-	-	-	16.25
Long-Term Leases	-	-	-	2.19	4.52
Other Long-Term Liabilities	-	-	-	0.03	-
Total Long-Term Liabilities	-	-	-	2.22	20.77
Total Liabilities	0.81	0.69	1.96	26.38	36.81
Common Stock	0	0	0	0.02	0.22
Additional Paid-in Capital	926.77	922.51	922.07	919.17	900.69
Retained Earnings	-924.62	-920.45	-915.77	-880.63	-842.85
Shareholders' Equity	2.15	2.06	6.31	38.56	58.06
Total Liabilities & Equity	2.97	2.76	8.26	64.94	94.87
Total Debt	0	0	0	19.51	29.37
Net Cash (Debt)	1.39	1.09	6.06	19.55	46.69
Net Cash Growth	26.95%	-82.00%	-68.99%	-58.13%	-57.65%
Net Cash Per Share	0.71	0.68	3.79	13.50	32.66
Book Value	2.15	2.06	6.31	38.56	58.06
Book Value Per Share	1.11	1.29	3.94	26.63	40.62
Tangible Book Value	2.15	2.06	6.31	38.56	58.06
Tangible Book Value Per Share	1.11	1.29	3.94	26.63	40.62

Updated Dec 31, 2025. Data Source: Fiscal.ai. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q